REFERENCES
1. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med . Sep 2010;363(14):1324-34. doi:10.1056/NEJMoa0911123
2. Yu AL, Gilman AL, Ozkaynak MF, et al. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res . Apr 15 2021;27(8):2179-2189. doi:10.1158/1078-0432.CCR-20-3909
3. Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.JAMA . 08 27 2019;322(8):746-755. doi:10.1001/jama.2019.11642
4. Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol . Sep 2013;14(10):999-1008. doi:10.1016/S1470-2045(13)70309-7
5. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1.Bone Marrow Transplant . Jul 2013;48(7):947-52. doi:10.1038/bmt.2012.276
6. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol . Mar 2009;27(7):1007-13. doi:10.1200/JCO.2007.13.8925
7. London WB, Castel V, Monclair T, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol . Aug 2011;29(24):3286-92. doi:10.1200/JCO.2010.34.3392
8. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med . Apr 1998;39(4):679-88.
9. Lumbroso JD, Guermazi F, Hartmann O, et al. Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans. Prog Clin Biol Res . 1988;271:689-705.
10. Claudiani F, Stimamiglio P, Bertolazzi L, et al. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.Q J Nucl Med . Dec 1995;39(4 Suppl 1):21-4.
11. Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring method–application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma.Eur J Cancer . 1995;31A(2):256-61. doi:10.1016/0959-8049(94)00509-4
12. Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. J Nucl Med . Apr 2013;54(4):541-8. doi:10.2967/jnumed.112.112334
13. Yanik GA, Parisi MT, Naranjo A, et al. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children’s Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med . 03 2018;59(3):502-508. doi:10.2967/jnumed.117.195883
14. Lewington V, Lambert B, Poetschger U, et al. I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel. Eur J Nucl Med Mol Imaging . Feb 2017;44(2):234-241. doi:10.1007/s00259-016-3516-0
15. Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers (Basel) . Jan 28 2020;12(2)doi:10.3390/cancers12020309
16. Ozkaynak MF, Gilman AL, London WB, et al. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931. Front Immunol . 2018;9:1355. doi:10.3389/fimmu.2018.01355
17. Matthay KK, Shulkin B, Ladenstein R, et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer . Apr 27 2010;102(9):1319-26. doi:10.1038/sj.bjc.6605621
18. Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol . Aug 2017;35(22):2580-2587. doi:10.1200/JCO.2016.72.0177
19. YOUDEN WJ. Index for rating diagnostic tests. Cancer . Jan 1950;3(1):32-5. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Journal of American Statistics . 1958;(53):457-481.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer . Jan 1977;35(1):1-39. doi:10.1038/bjc.1977.1
22. Decarolis B, Schneider C, Hero B, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol . Mar 01 2013;31(7):944-51. doi:10.1200/JCO.2012.45.8794
23. Ladenstein R, Lambert B, Pötschger U, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.Eur J Nucl Med Mol Imaging . Feb 2018;45(2):292-305. doi:10.1007/s00259-017-3829-7
24. Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer . Jul 2008;44(11):1552-8. doi:10.1016/j.ejca.2008.03.013
TABLES
TABLE 1 Patient characteristics at diagnosis